Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Singular Genomics Systems, Inc. OMIC
$1.02
-$0.05 (-5.14%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
74099337.00000000
-
week52high
4.80
-
week52low
0.92
-
Revenue
765000
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-1.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| UBS | Neutral | Buy | 17 авг 2022 г. |
| Goldman Sachs | Neutral | Buy | 10 авг 2022 г. |
| B of A Securities | Underperform | Buy | 10 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 14 июл 2022 г. |
| Goldman Sachs | Buy | Buy | 11 мая 2022 г. |
| Goldman Sachs | Neutral | Neutral | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Glezer Eli N. | A | 4185000 | 50000 | 12 дек 2022 г. |
| Spaventa Andrew | D | 3913571 | 500000 | 04 окт 2022 г. |
| BARKER DAVID L | D | 0 | 60000 | 07 июл 2022 г. |
| BARKER DAVID L | A | 60000 | 60000 | 07 июл 2022 г. |
| Pellini Michael J | D | 0 | 60000 | 31 мая 2022 г. |
| Pellini Michael J | D | 99289 | 154939 | 31 мая 2022 г. |
| Pellini Michael J | A | 254228 | 60000 | 31 мая 2022 г. |
| Pellini Michael J | A | 194228 | 34271 | 31 мая 2022 г. |
| Pellini Michael J | A | 159957 | 60668 | 31 мая 2022 г. |
| Pellini Michael J | A | 62500 | 62500 | 26 мая 2022 г. |
Новостная лента
Singular Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
21 дек 2022 г. в 16:05
SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Singular Genomics Systems, Inc. (OMIC) Q3 2022 Earnings Call Transcript
Seeking Alpha
07 ноя 2022 г. в 23:49
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Bruce Spaventa - Founder and Chief Executive Officer Dalen Meeter - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Tom Stevens - Cowen John Sourbeer - UBS Operator Good day, ladies and gentlemen and welcome to the Singular Genomics Systems, Inc. Third Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Philip Taylor, Investor Relations for Singular Genomics.
Singular Genomics to Report Third Quarter 2022 Financial Results on November 7, 2022
GlobeNewsWire
24 окт 2022 г. в 16:05
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
GlobeNewsWire
18 авг 2022 г. в 16:05
SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.
Singular Genomics Systems, Inc. (OMIC) CEO Drew Spaventa on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
13 авг 2022 г. в 16:13
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder & CEO Dalen Meeter - Head, Finance Eli Glezer - Founder and Chief Scientific Officer Conference Call Participants Dan Brennan - Cowen Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Good day, ladies and gentlemen, and welcome to the Singular Genomics Systems, Incorporated Second Quarter 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be opened for questions and comments after the presentation.